In the realm of diabetes and obesity, pharmaceutical companies worldwide are continuously conducting research. Amidst this, a major Danish pharmaceutical company, Novo Nordisk, has discovered a chemical compound that promises to be a lifeline for diabetes and obesity patients worldwide.
Global Obesity Crisis Intensifies as India Grapples with Diabetes Capital Title, Novo Nordisk Unveils Lifesaving Treatment
Diabetes, often dubbed as the capital of India, coupled with the global epidemic of obesity, has raised significant concerns. A recent report published in the medical journal The Lancet reveals that over a billion people worldwide are affected by obesity.
According to the study published in The Lancet, more than 880 million adults and 159 million children worldwide are obese. In the case of obesity, Indian men rank 21st globally, and women rank 19th. A study conducted by the Indian Council of Medical Research revealed that in 2021, India had 100.1 million diabetic patients and 136 million pre-diabetic individuals. Recent data from the National Family Health Survey (NFHS-5) indicates that 24% of women and 22.9% of men in India are affected by obesity or overweight.
While research on obesity and diabetes continues, Novo Nordisk from Denmark has discovered a chemical compound that could serve as a lifesaver for the diabetes capital of the world. This compound, named Semaglutide, is being formulated into a new medication called Ozempic. Ozempic is not only a boon for diabetes patients but also proves effective for individuals struggling with obesity.
Ozempic’s Effectiveness Draws Global Attention, But Concerns Mount Over Side Effects
Ozempic and its variants have garnered attention worldwide for their effectiveness. The medication not only stimulates the pancreas to produce insulin but also helps in controlling blood sugar levels and reducing appetite. Ozempic has gained popularity, especially in the United States, where it is being used extensively to treat type 2 diabetes patients. The cost of one dose of Ozempic is approximately ₹1.08 lakh.
However, the widespread use of Ozempic has raised concerns about its side effects. Medical experts caution that nearly three-quarters of patients may experience side effects such as reduced appetite, nausea, vomiting, and abdominal pain. Moreover, there is a risk of gastrointestinal paralysis associated with this medication.
Dr. Naval Kishore Vikram, an expert in diabetes at AIIMS Delhi, describes Ozempic as a breakthrough for patients struggling with obesity and diabetes. He emphasizes that this medication works effectively by targeting various areas of the body, controlling blood sugar levels, appetite, and exerting an impact on the brain.
Exploring the Risks and Alternatives of Ozempic and Its Variants in Diabetes Treatment
Although Ozempic and its variants offer promising benefits, they also come with significant risks and are not suitable for all patients. Individuals with thyroid disorders, pancreatic cancer, or intestinal cancer need to exercise caution while using this medication.
In addition to Ozempic, other variants such as Monjaro, Jardiance, Victoza, and Rybelsus are also available in the market, each catering to specific needs. Rybelsus, approved in India in 2022, is tailored for type 2 diabetes patients. The cost of these medications varies, with prices ranging from ₹3,170 to ₹3,870 for oral tablets and ₹6,957 for injectables.
Ozempic and its counterparts represent a significant advancement in diabetes and obesity treatment. While offering hope for millions of patients worldwide, it’s essential to consider the potential side effects and suitability for individual patients before prescribing these medications.